Wilson, MW; Shu, L; Hinkovska-Galcheva, V; Jin, Y; Rajeswaran, W; Abe, A; Zhao, T; Luo, R; Wang, L; Wen, B; et al.
Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.
ACS Chemical Neuroscience.
2020;
11:3464-3473.
Davis, HW; Vallabhapurapu, SD; Chu, Z; Wyder, MA; Greis, KD; Fannin, V; Sun, Y; Desai, PB; Pak, KY; Gray, BD; et al.
Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles.
Cells.
2020;
9:E1960.
Sun, Y; Liou, B; Chu, Z; Fannin, V; Blackwood, R; Peng, Y; Grabowski, GA; Davis, HW; Qi, X.
Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease.
EBioMedicine.
2020;
55:102735.
Di Martino, S; Tardia, P; Cilibrasi, V; Caputo, S; Mazzonna, M; Russo, D; Penna, I; Realini, N; Margaroli, N; Migliore, M; et al.
Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors.
Journal of Medicinal Chemistry.
2020;
63:3634-3664.
Miranda, CJ; Chisari, E; Northcott, N; Pandya, J; Liou, B; Fannin, V; Blackwood, R; Dane, A; Kia, A; Canavese, M; et al.
One-off liver directed AAV gene therapy achieves long term uptake of acid beta-glucocerebrosidase by macrophages of affected tissues in Gaucher disease.
Molecular Genetics and Metabolism.
2020;
129:s110.
Zhao, X; Hettinghouse, A; Liou, B; Fannin, V; Blackwood, R; Liu, C; Sun, Y.
The therapeutic effect of progranulin derived Pcgin on neuronopathic Gaucher disease.
Molecular Genetics and Metabolism.
2020;
129:s165-s166.
Schiffer, V; Santiago-Mujika, E; Flunkert, S; Schmidt, S; Farcher, M; Loeffler, T; Schilcher, I; Posch, M; Neddens, J; Sun, Y; et al.
Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease.
Editor, Silman I.
PloS one.
2020;
15:e0227077.